Harwell, Oxford, June23, 2025, MitoRx Therapeutics Limited (MitoRx), a platform biotech company developing novel mitochondrial-targeted persulfide modifiers, today announces additional results for its novel small molecule Myo4 targeting obesity. The additional data shows that its small molecule persulfide modifiers can restore insulin sensitivity in an industry-standard murine diet-induced obesity model.

These results are shown in a poster presentation by MitoRx co-founder, Professor Matt Whiteman, and Xavier Jacq, MitoRx’s CSO, at the 85^thScientific Sessions of the American Diabetes Association (ADA) in Chicago. The poster is entitled "The novel small molecule Myo4 normalises glycemic control, reduces weight/fat mass and prevents semaglutide-induced muscle remodelling in the murine diet-induced obesity model"

These supplementary data on restoration of insulin sensitivity builds on results recently presented at the 32nd European Congress on Obesity, which demonstrated that Myo4 monotherapy drives fat loss while preserving both muscle and bone mineral content. MitoRx also provided additional data demonstrating an accentuation of fat loss with complete muscle preservation when Myo4 is used in combination with semaglutide.

There are currently nearly 890 million people living with obesity worldwide, with 1.6 billion adults with overweight based on body mass index (BMI) category. The global economic impact of obesity is expected to be over USD 4 trillion by 2035, and USD 18 trillion by 2060.

“These additional preclinical results provide further confirmation for the potential of the small molecule Myo4. This demonstrates our approach can restore insulin sensitivity in addition to maintaining lean muscle mass whilst reducing fat” said Xavier Jacq, CSO, MitoRx. “These data provide further demonstration of the potential of Myo4 to vastly increase the quality of weight loss overcurrent GLP-1 options.”

“The treatment of obesity to date has been revolutionized by GLP-1s, but they come with significant drawbacks,” saidJon Rees, CEO, MitoRx. “MitoRx’s development of Myo4 offers a novel root cause mechanism-of-action orthogonal to GLP-1s, exploiting a known metabolic impairment to addressing the underlying cause of obesity with the potential to lead the next generation of improved treatments for weight loss leading to better cardiometabolic health.”

About Myo4 and other platform compounds

Myo4 was developed by MitoRx as an improved mitochondrial-targeted persulfide modifier. These results enable MitoRx to move Myo4 toward clinical candidate nomination.